TrkA 

 74 Products   74 Products   309 Diseases   14399 News 


12345678910111213...168169»
  • ||||||||||  Dovbleron (taletrectinib) / Nuvation Bio
    Journal:  Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. (Pubmed Central) -  Apr 3, 2025   
    The patient continued adjuvant entrectinib therapy and has remained recurrence-free during follow-up, with 21 Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-na
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Efficacy and safety of larotrectinib as first-line treatment for adult patients with TRK fusion cancer (Villa Ciani) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_260;    
    P1, P1/2,
    Conclusions Laro demonstrates rapid and durable responses, extended survival and a favourable safety profile in adult pts without prior systemic therapy. This supports the use of laro in a first-line setting and the wider adoption of NGS panels that include NTRK gene fusions to identify adult pts who may benefit from targeted treatment.
  • ||||||||||  Qinlock (ripretinib) / Ono Pharma, Stivarga (regorafenib) / Bayer
    Optimizing second-line therapy for advanced gastrointestinal stromal tumors: Real-world efficacy and safety analysis (Villa Ciani) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_258;    
    P
    Median PFS (mPFS) for ripretinib, sunitinib and regorafenib was 11.4, 12.4 and 2.8 months, respectively (p=0.296)...Conclusions Our preliminary results suggest that ripretinib may offer superior clinical benefits for patients with primary KIT exon 11 mutations after failure of imatinib first-line treatment...Editorial acknowledgement Legal entity responsible for the study The authors. Funding Has not received any funding.
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Treatment discontinuation outcomes in paediatric patients with TRK fusion sarcomas treated with larotrectinib (Hall A) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_157;    
    P1/2
    Conclusions Laro demonstrated robust, durable responses and favourable safety in paediatric pts with TRK fusion sarcomas who had a drug holiday. Stopping treatment is feasible following surgical resection or durable response, with most pts benefitting clinically with laro resumption on disease progression.
  • ||||||||||  Retevmo (selpercatinib) / Eli Lilly, Gavreto (pralsetinib) / Rigel
    Review, Journal:  Treatment of non-small cell lung cancer with RET rearrangements. (Pubmed Central) -  Apr 2, 2025   
    Selpercatinib has shown superiority over chemotherapy in a phase 3 study (LIBRETTO-431) in previously untreated patients with RET fusion-positive NSCLC, which established its place as the standard of care in this patient population. This review discusses the biology and clinical characteristics of RET-rearranged NSCLC and summarizes the evolution of treatment strategies, current understanding of mechanisms of resistance, and development of new-generation agents to overcome resistance.
  • ||||||||||  Review, Journal:  Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. (Pubmed Central) -  Apr 2, 2025   
    First-generation inhibitors, such as crizotinib and entrectinib, have demonstrated impressive efficacy, with objective response rates exceeding 60%-70%...Next-generation TKIs, including lorlatinib, taletrectinib, and repotrectinib, have been developed to overcome these challenges...Zidesamtinib, a highly selective next-generation ROS1 inhibitor, further addresses TRK-mediated off-target neurological toxicities seen with prior agents, and is poised to offer improved tolerability...In addition, the development of novel diagnostic tools, including RNA-based next-generation sequencing, has enhanced the detection of functional ROS1 fusions by ensuring that patients with actionable mutations receive appropriate targeted therapies. These advances highlight the evolving landscape of treatment for ROS1-positive NSCLC, with the aim of maximizing long-term survival and quality of life.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, Vitrakvi (larotrectinib) / Bayer
    Review, Journal:  Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites. (Pubmed Central) -  Mar 28, 2025   
    NTRK fusions are rare, with wide prevalence variability among cancer types. The findings highlight the need for standardized diagnostic methods and larger real-world studies to improve prevalence estimates and assess the impact of NTRK fusions on outcomes, ultimately aiding in the optimization of targeted treatments for affected patients.
  • ||||||||||  Journal:  Sequential Treatment with Regorafenib and Trifluridine/Tipiracil  (Pubmed Central) -  Mar 28, 2025   
    This study did not show a statistically significant difference in OS with R-T versus T-R. Although limited by its retrospective nature, the study suggested R-T may be preferable to T-R given the observed reduction in neutropenia/myelosuppression-related treatments.
  • ||||||||||  Review, Journal, MSi-H Biomarker, IO biomarker:  What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT. (Pubmed Central) -  Mar 27, 2025   
    Ongoing clinical trials with novel agents and combinations are expected to provide further clarity on optimizing sequential treatment regimens and personalizing therapy for mCRC patients. This review emphasizes the need for comprehensive molecular profiling and shared decision-making to improve outcomes and quality of life in this challenging patient population.
  • ||||||||||  VC004 / Jiangsu Vcare Pharma
    Enrollment open, Trial initiation date:  Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors (clinicaltrials.gov) -  Mar 20, 2025   
    P3,  N=54, Recruiting, 
    RPL14 plays a key role in PRMT5-driven enhancement of DNA damage repair and reduced drug sensitivity, identifying RPL14 as a potential therapeutic target to overcome regorafenib resistance in HCC. Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025
  • ||||||||||  Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. (Pubmed Central) -  Mar 19, 2025   
    Tumor-agnostic and N-of-1 clinical trials have challenged traditional clinical trial paradigms and provide the foundation for truly personalized oncology for patients with these aggressive cancers. Further work is needed to determine how to leverage these novel approaches into the management of operable disease.
  • ||||||||||  Review, Journal:  Systemic Therapies for Advanced Medullary Thyroid Carcinoma. (Pubmed Central) -  Mar 19, 2025   
    Cabozantinib and vandetanib, multikinase inhibitors (MKIs) that exert their therapeutic effect mainly through antiangiogenesis by targeting the vascular endothelial growth factor receptor, have mild anti-RET activity...Potent and selective RET inhibitors, selpercatinib and pralsetinib, demonstrate significant efficacy in RET-altered cancers and more tolerable side effect profiles than MKIs...Thus, development of more effective treatments for advanced, progressive MTC remains an urgent priority. In this chapter, we describe the current spectrum of systemic therapies for MTC, their limitations, and ongoing investigations.
  • ||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date:  A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (clinicaltrials.gov) -  Mar 19, 2025   
    P2,  N=39, Active, not recruiting, 
    In this chapter, we describe the current spectrum of systemic therapies for MTC, their limitations, and ongoing investigations. Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Cabometyx (cabozantinib tablet) / Exelixis
    Trial completion date:  Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (clinicaltrials.gov) -  Mar 18, 2025   
    P2,  N=22, Active, not recruiting, 
    The addition of lenvatinib or regorafenib may provide promising incremental benefit for patients with aHCC. Trial completion date: Feb 2025 --> Dec 2025